Inocras Expands WGS-Based Cancer Precision Diagnostics CancerVision™ to 10 Hospitals

SAN DIEGO--(BUSINESS WIRE)--Today, Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, operating a CLIA/CAP-certified laboratory in San Diego, announced that its whole genome sequencing (WGS)-based cancer diagnostics platform, CancerVision, has been officially listed and is available for real-world patient care at 10 major hospitals across South Korea.

The hospitals that have formally listed CancerVision for patient care include leading academic medical centers, university hospitals, and specialized cancer treatment facilities nationwide. These institutions represent key oncology hubs serving diverse patient populations throughout South Korea.

CancerVision performs whole genome sequencing to analyze patients' entire genomic profiles. This genome-wide analysis enables detection of rare variants, structural variations, and complex genetic characteristics that may be missed by conventional panel-based testing, helping clinicians access more detailed information to support treatment planning.

CancerVision reports are delivered in clinical-grade format specifically designed for real-world patient care workflows. The reports contain actionable genomic information that can be directly utilized for individual cancer patients' drug selection and treatment strategy development.

"The official listing of CancerVision for patient care demonstrates that WGS-based diagnostic technology has moved beyond the research phase to prove clinical value in actual patient treatment decisions," said Jehee Suh, CEO of Inocras. "This enables clinicians to utilize more comprehensive genomic information that was previously unavailable through conventional testing methods."

The formal listing at these 10 hospitals means CancerVision is now integrated into clinical practice, allowing physicians to prescribe the test as part of standard patient care protocols. This represents an evolution from research applications to an established clinical tool in cancer treatment.

Since 2024, Inocras has pursued this clinical adoption strategy, working closely with hospital administrators and oncology departments to demonstrate the clinical value of WGS-based analysis. This achievement marks an important milestone, showing that WGS-based analysis technology has reached practical utility in patient care and treatment decision-making.

About Inocras Inc.:

Inocras is an AI-driven company that specializes in delivering critical insights to cancer and rare disease patients through whole genome sequencing and bioinformatics. The company offers its whole genome testing products, CancerVision, RareVision and MRDVision, and provides research services for pharmaceutical and biotechnology companies as well as research organizations through its CAP/CLIA lab, powered by its proprietary, IP-protected bioinformatics pipeline. Inocras is dedicated to unlocking the potential of whole genome data to enable precision health for everyone. For more information, please visit inocras.com and follow the Inocras LinkedIn page.